The Rothenberg CURED Lab offers information about news coverage and happenings involving members of our lab, the division, division programs (Drug Allergy Program, Food Allergy Program, Transition and Adult Immunodeficiency Program) and the Cincinnati Center for Eosinophilic Disorders (CCED).
There is a compensatory increase in the allergy-driving proteins (e.g., type 2 cytokines) in benralizumab-treated eosinophilic gastritis (EoG), supporting a regulatory role for eosinophils in EoG rather than a simple pro-inflammatory function and providing a rationale for anti–type 2 therapy rather than eosinophil depletion monotherapy for eosinophilic gastrointestinal diseases.” ~Marc Rothenberg, MD, PhD.
As connective tissue disorders and esophageal connective tissue alterations are associated with eosinophilic esophagitis (EoE), we evaluated a connective tissue disorder medication, losartan, on esophageal pathology, symptoms, and safety in patients with EoE with and without a connective tissue disorder in an open-label, non-placebo controlled multisite study. Losartan treatment was associated with improved patient-reported outcome scores and EoE Diagnostic Panel biomarkers although it did not reduce esophageal eosinophilia overall. A subset of patients demonstrated improved histopathologic and endoscopic features. Losartan may represent a future medication for the treatment of EoE but merits further study.
In this video, you’ll hear the story of a young patient with eosinophilic esophagitis (EoE) named Joe, and how the Cincinnati Center for Eosinophilic Disorders has a made a difference in his life. Joe and his mom talk about the benefits of collaborative care.
Eosinophilic diseases are lifelong conditions. Symptoms do not always correlate with disease activity, making it important to regularly monitor disease activity. Endoscopies can help your child’s physician determine the activity of eosinophilic disease at a given time and how well a treatment works for your child.
The new technology of transnasal endoscopy (TNE) is a means of doing an endoscopy quickly and efficiently in an office setting without requiring anesthesia. Cincinnati Children’s is now performing TNE for established patients.
“This trial calls into question the clinical relevance of monitoring EoE for treatment effect solely on the basis of the degree of eosinophilic inflammation. Future therapeutic strategies may involve broader targets or those higher upstream in pathogenic pathways.” ~Marc Rothenberg, MD, PhD
The US Food and Drug Administration initially approved the drug dupilumab for treating EoE in 2022, but only for adults and teens. Based on data from this more recent clinical trial focusing on younger children, the FDA acted in January 2024 to extend approval to children aged 1 to 12 years who weigh at least 15 kg (about 33 pounds).
National Eosinophil Awareness Week is May 19-25, 2024! To kick off National Eosinophil Awareness Week, watch the highlight video of the 7th CURED EGID Patient Education and Research Conference, which was held April 4-7, 2024 at Cincinnati Children's Hospital Medical Center.
Highlight Video: 7th CURED EGID Patient Education and Research Conference
The Rothenberg CURED Lab tapped into machine learning protocol to learn more about papillary mast cells, a potential reservoir of harmful cells seen in active eosinophilic esophagitis (EoE). Read the Science Blog
The 7th CURED Patient Education Research Conference was held April 4-7, 2024 at Cincinnati Children's Hospital Medical Center. There were over 165 professionals, 50 patients and families, and 100 virtual attendee registrants, and 11 company sponsors. The attendees were from 4 continents, 8 countries, and 33 states, and over 40 late-breaking abstracts were presented at the poster session. Thank you, CURED, for a great conference!
Join us April 4-7, 2024 at Cincinnati Children's Hospital Medical Center for the Campaign Urging Research for Eosinophilic Diseases (CURED) Patient Education Research Conference.
The conference features subject experts from around the world speaking on a variety of topics including the clinical, pathogenic, genetic, dietary features and therapies of EGID. Breakthroughs in novel therapeutic strategies with a focus on the pipeline of FDA-approved drugs will be discussed.
In person attendance provides an opportunity to engage with 55 experts and directly view 45 research posters with the scientific presenters. In person attendance also provides an interactive tour of our research laboratory.
“It is wonderful to now have approval of Dupilumab for young children. This is particularly important since the disease often develops in early life including the first 18 months of age.” ~Marc Rothenberg, MD, PhD. Read News Release
Exciting news from Takeda for patients with EoE ages 11 and up.
“This is great news for the EoE community, involving huge efforts by researchers, patients and industry.” ~Marc Rothenberg, MD, PhD. Read News Release
7th CURED Patient Education Research Conference
Join us April 4-7, 2024 at Cincinnati Children's Hospital Medical Center for the Campaign Urging Research for Eosinophilic Diseases (CURED) Patient Education Research Conference.
"As we roll into the New Year, I am pleased to share this video of the amazing accomplishments of the Division of Allergy and Immunology at Cincinnati Children’s over the last year. Wishing everyone a happy new year and expectations that we will continue to move science and patient care ahead in a truly impactful and meaningful manner." ~ Marc Rothenberg, MD, PhD.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
